# Design Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/design-therapeutics

- Industry: Biotechnology
- Headquarters: Carlsbad, US
- Website: www.designtx.com
- Total disclosed funding: $171M
- Latest round: Series B (Jan 25, 2021)
- Investors on record: 13

## About

Design Therapeutics Inc. is a US-based biopharmaceutical company focused on developing small molecule therapies to treat serious genetic diseases, leveraging its proprietary GeneTAC platform to create targeted treatment options. Design Therapeutics Inc. specializes in developing solutions for monogenic repeat expansion disorders. Founded by Pratik Shah, the company is headquartered in Carlsbad, US. The company raised USD 240.00 mn in an IPO on March 25, 2021, marking a significant funding milestone, bringing the total amount raised to USD 240.00 mn. Design Therapeutics focuses on creating innovative small molecule therapeutic candidates targeting genetic diseases without effective treatments. Their GeneTAC (Gene Targeted Chimera) platform addresses conditions such as Friedreich ataxia and Huntington’s disease. Their products primarily target patients with these disorders and are marketed mainly in the United States, with potential for future expansion. Revenue generation is facilitated through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies, focusing on licensing agreements and collaborative research.

## Funding rounds

- Series B, Jan 25, 2021, $125M — T Rowe Price, SR One, Vivo Capital, Wellington Management, Surveyor Capital, West River Group, BlackRock, RA Capital Management, Cormorant Asset Management, Avoro Capital Advisors, Janus Henderson Investors, Quan Capital, Logos Capital
- Series A, Mar 20, 2020, $46M — SR One, West River Group, Cormorant Asset Management, Quan Capital

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- West River Group — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Surveyor Capital — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Avoro Capital Advisors — Series B
- Janus Henderson Investors — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B